Percutaneous oestrogen therapy opposed by lynestrenol or natural progesterone--effects on circulating oestrogens, FSH, sex hormone binding globulin and pregnancy zone protein.
Three groups of post-menopausal women were treated with percutaneous 17 beta-oestradiol 3 mg daily opposed by lynestrenol 5 mg or natural micronized progesterone 200 mg and 300 mg, respectively. During 6 mth of cyclic replacement oestrogen serum levels were increased corresponding to follicular phase values. The pre-treatment ratio E1/E2 was unchanged which is in contrast to oral therapy. Progesterone had a much weaker effect on FSH levels than lynestrenol. Women treated with progestogen had regular withdrawal bleedings, while the micronized progesterone was insufficient in this respect. No increase of the oestrogen-sensitive liver proteins, sex hormone binding globulin (SHBG) and pregnancy zone protein (PZP), was recorded in spite of a marked increase in circulating oestrogens.
D002979:Climacteric; D004958:Estradiol / Q000008:administration & dosage* / Q000097:blood; D004967:Estrogens / Q000097:blood*; D004970:Estrone / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood*; D005782:Gels; D006801:Humans; D008234:Lynestrenol / Q000627:therapeutic use*; D008875:Middle Aged; D011257:Pregnancy Proteins / Q000032:analysis; D011374:Progesterone / Q000627:therapeutic use*; D012738:Sex Hormone-Binding Globulin / Q000032:analysis; D012869:Skin Absorption
D004967:Estrogens; D005782:Gels; D011257:Pregnancy Proteins; D012738:Sex Hormone-Binding Globulin; D004970:Estrone; D011374:Progesterone; D004958:Estradiol; D005640:Follicle Stimulating Hormone; D008234:Lynestrenol